WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 413482
CAS#: 36508-71-1 (HCl)
Description: Zorubicin HCl is an Antineoplastic
MedKoo Cat#: 413482
Name: Zorubicin HCl
CAS#: 36508-71-1 (HCl)
Chemical Formula: C34H36ClN3O10
Exact Mass:
Molecular Weight: 682.12
Elemental Analysis: C, 59.87; H, 5.32; Cl, 5.20; N, 6.16; O, 23.45
Related CAS #: 36508-71-1 (HCl) 54083-22-6 (free base)
Synonym: Zorubicin HCl; NSC164011; NSC-164011; NSC 164011
IUPAC/Chemical Name: N'-((E)-1-((2S,4S)-4-(((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-2-yl)ethylidene)benzohydrazide hydrochloride
InChi Key: NKFHKYQGZDAKMX-PPRKPIOESA-N
InChi Code: InChI=1S/C34H35N3O10.ClH/c1-15-28(38)20(35)12-23(46-15)47-22-14-34(44,16(2)36-37-33(43)17-8-5-4-6-9-17)13-19-25(22)32(42)27-26(30(19)40)29(39)18-10-7-11-21(45-3)24(18)31(27)41;/h4-11,15,20,22-23,28,38,40,42,44H,12-14,35H2,1-3H3,(H,37,43);1H/b36-16+;/t15-,20-,22-,23-,28+,34-;/m0./s1
SMILES Code: COc1c2c(C(c3c(C2=O)c(O)c4c(C[C@](C[C@@H]4O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O)N)(/C(C)=N/NC(c6ccccc6)=O)O)c3O)=O)ccc1.Cl
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: to be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 682.12 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Deng S, Cui CX, Duan L, Hu L, Yang X, Wang JC, Qu LB, Zhang Y. Anticancer Drug Release System Based on Hollow Silica Nanocarriers Triggered by Tumor Cellular Microenvironments. ACS Omega. 2020 Dec 29;6(1):553-558. doi: 10.1021/acsomega.0c05032. PMID: 33458507; PMCID: PMC7807753.
2: Poochikian GK, Cradock JC, Flora KP. Stability of anthracycline antitumor agents in four infusion fluids. Am J Hosp Pharm. 1981 Apr;38(4):483-6. PMID: 6945043.
3: Jaiyesimi IA, Kantarjian HM, Estey EH. Advances in therapy for hairy cell leukemia. A review. Cancer. 1993 Jul 1;72(1):5-16. doi: 10.1002/1097-0142(19930701)72:1<5::aid-cncr2820720104>3.0.co;2-y. PMID: 7685243.
4: Alberts DS, Van Daalen Wetters T. Rubidazone vs adriamycin: an evaluation of their differential toxicity in the spleen colony assay system. Br J Cancer. 1976 Jul;34(1):64-8. doi: 10.1038/bjc.1976.123. PMID: 952715; PMCID: PMC2025119.
